Depomed’s Gabapentin GR Fails Phase III Postherpetic Neuralgia Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcome is not expected to affect product’s ongoing clinical development for menopausal hot flashes.
You may also be interested in...
Depomed Revises Protocol For Gabapentin GR Postherpetic Neuralgia Phase III
After the initial Phase III trial of the extended-release drug failed to show a benefit over placebo in PHN, Depomed gives it another go.
Depomed Revises Protocol For Gabapentin GR Postherpetic Neuralgia Phase III
After the initial Phase III trial of the extended-release drug failed to show a benefit over placebo in PHN, Depomed gives it another go.
NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia
Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.